Advanced Tumors Clinical Trial
Official title:
A Phase I/IIa Study to Evaluate the Tolerance, Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of PM1022 in Patients With Advanced Tumors
This study incluces a phase I study to evaluate the tolerance, safety, pharmacokinetic characteristics and preliminary efficacy of PM1022 in patients with advanced tumors and a phase IIa study to investigate the efficacy of PM1022 in patients with advanced tumors.
PM1022 is a recombinant humanized anti-PDL1 and anti-TIGIT bispecific antibody. This Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinical expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of PM1022 administered as a single-agent by IV infusion every 3 weeks to patients with locally advanced or metastatic solid malignancies, who have failed or are intolerant to standard therapy, or for whom no standard therapy is available. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06245122 -
A Study of CS23546 in Subjects With Advanced Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06314087 -
iTAPVR Study - Phase II Randomized Study
|
Phase 2 | |
| Recruiting |
NCT05390528 -
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02419417 -
Study of BMS-986158 in Subjects With Select Advanced Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT04808453 -
Phase I Study of CPI-300 in Patients With Advanced Tumors
|
Phase 1 | |
| Recruiting |
NCT05799183 -
A SHR-1210 BE Study on Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05429008 -
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
|
Phase 1 | |
| Terminated |
NCT04198818 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05213767 -
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT04151810 -
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05068856 -
A Study of HRS2543 in Patients With Advanced Tumors
|
Phase 1 | |
| Completed |
NCT03781362 -
Study of CPI-100 in Patients With Advanced Tumors
|
Phase 1 | |
| Recruiting |
NCT03908814 -
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05061628 -
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
|
Phase 1 | |
| Recruiting |
NCT03444714 -
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
|
Phase 1 |